

Obesity

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity

Trial Status Not yet recruiting	Trial Runs In	Trial Identifier NCT07843498 2026-526188-39-00 CC46368
---	----------------------	---

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide vs. Placebo in Participants With Overweight or Obesity

Trial Summary:

This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity, at least one weight-related comorbidity, and without Type 2 Diabetes (T2D).

Hoffmann-La Roche Sponsor	Phase 3 Phase
NCT07843498 2026-526188-39-00 CC46368 Trial Identifiers	

Eligibility Criteria:

Gender All	Age #18 Years	Healthy Volunteers No
----------------------	-------------------------	---------------------------------

Inclusion Criteria:

- Participants with BMI # 30 kg/m² or BMI # 27 kg/m² with at least one weight-related comorbidity
- History of at least one self-reported unsuccessful dietary effort to lose body weight

Exclusion Criteria:

ForPatients

by Roche

- HbA1c # 48 mmol/mol (6.5%), measured by the central laboratory at screening
- Known history of Type 1 or Type 2 diabetes mellitus
- Current or previous treatment with petrelintide or any other amylin analog